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Abstract
Background: For the past two decades multiple series have documented that liver resection has
become safer. The purpose of this study was to determine the current status of hepatic resection in the
USA by analysing the multi-institutional experience within the National Surgical Quality Improvement
Program (NSQIP) dataset.
Methods: Of the 363 897 cases in the 2005–2007 NSQIP Participant Use File, 2313 elective open
hepatectomy cases were identified (1344 partial, 230 left, 510 right and 229 extended hepatectomies). A
total of 57 perioperative risk factors and 28 postoperative complications were compared. To determine
the applicability of NSQIP general risk models to hepatic surgery, the prognostic value of standard
multivariate analysis was compared with the NSQIP general surgery aggregate risk indices (expected
probability of morbidity [morbprob], expected probability of mortality [mortprob]).
Results: The median age of patients listed in the database was 60 years; sex distributions were
equivalent; 78% were White; 65% of patients had an ASA score of 3 or 4, and the most prevalent
co-morbidity was hypertension (46%). A total of 41% of patients had disseminated cancer, 19% of whom
had received chemotherapy within 30 days of surgery. The overall 30-day mortality rate was 2.5%
(57/2313) and the 30-day major morbidity rate was 19.6% (453/2313). Multivariate analysis identified nine
risk factors associated with major morbidity and two risk factors associated with mortality. In contrast, the
morbprob and mortprob statistics did not predict outcomes accurately. For those patients who developed
major morbidity, the median length of stay was longer (10 vs. 6 days; P = 0.001) and the mortality rate was
higher (11.3% vs. 0.3%; P = 0.001).
Conclusions: Analysis of the NSQIP experience with hepatectomy indicates that the current mortality
and major morbidity rate benchmarks are 2.5% and 19.6%, respectively. Poor outcomes were associated
with nutritional status, liver function and the extent of hepatectomy. The NSQIP general surgery morbprob
and mortprob values were relatively poor predictors of post-hepatectomy observed morbidity, indicating
the need for specialty-specific NSQIP modelling.
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Introduction
For the past two decades multiple series have documented that
liver resection has become safer.1 Several relatively large, single-
institution experiences have been reported documenting overall
morbidity and mortality rates for hepatectomy.2–10 In addition,
these studies have identified several perioperative clinical factors
associated with poor post-hepatectomy outcomes. However,
these data are weakened by the fact that they are derived
from mainly institutional experiences that may not be applicable
to general hepatic surgery practices and few of them represent a
modern experience.
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To address these weaknesses and to update the morbidity and
mortality rates that should be expected following hepatectomy, we
examined the National Surgical Quality Improvement Program
(NSQIP) public use file (PUF) dataset. The recently released
2005–2007 PUF dataset includes 363 897 cases contributed by
over 120 member institutions of variable size and type of practice.
The NSQIP, recently described by the Institute of Medicine as
the ‘best in the nation’ for measuring and reporting surgical
quality and outcomes, is based on three important quality mea-
surement principles.11 Firstly, specially trained nurse reviewers
collect and enter all NSQIP risk factor and outcomes data inde-
pendently of the possible bias inherent in the traditional ‘surgical
databases’ used in clinical research. Secondly, 30-day follow-up is
obtained in all cases regardless of postoperative admission status.
In other words, NSQIP nurses will account for postoperative mor-
bidity and mortality at 30 days from operation, even if the patient
is discharged from the operative admission, thereby significantly
increasing the accuracy and thoroughness of reporting. Thirdly,
cases are categorized by current procedural terminology (CPT)
code, leading to the standardization of reporting and analysis
across member institutions.
From these data, the NSQIP has been able to develop robust
predictive models across broad categories, such as general and
vascular surgery.12 Given the rapid increase in patients in the
dataset, the NSQIP is examining the applicability of the NSQIP
models in assessing specialty-specific outcomes. One area of
emphasis is hepatopancreatobiliary (HPB) surgery. Currently,
HPB-specific outcomes (e.g. pancreatic fistula following pancre-
atectomy) are not recorded in the NSQIP dataset, but over 25
detailed surgical outcomes are collected. Combined, these factors
predict that the NSQIP dataset will be an extremely valuable
instrument with which to determine the true and current inci-
dence of morbidity and mortality following major hepatic surgery
in America. These data have value not only for surgeons, but also
for patients and for the oncologists and gastroenterologists who
refer patients for surgical evaluation.
Materials and methods
Of the 363 897 cases in the 2005–2007 NSQIP PUF, 2313 elective
open hepatectomy cases were identified.13,14 Emergency cases were
excluded from analysis. Included in this subset were 1344 partial
hepatectomies (58%), 230 left hepatectomies (10%), 510 right
hepatectomies (22%) and 229 extended hepatectomies (10%).
The clinical characteristics of these patients are detailed in Table 1.
For each patient, 43 preoperative risk factors, 13 preoperative
laboratory values, 14 perioperative risk factors and 28 postopera-
tive complications (also termed ‘occurrences’) were assessed. In
addition to traditional prognostic clinical variables, the NSQIP-
derived ‘mortprob’ and ‘morbprob’ estimates were statistically
assessed to determine their applicability to liver resection patients.
The mortprob and morbprob are calculated values that assess the
expected mortality and morbidity rates for each patient based on
complex risk models created from the entire NSQIP dataset. To
date, the mortprob and morbprob statistics have been derived from
an analysis of outcomes for all patients in the NSQIP dataset. In this
general setting, they have strong predictive value. However, the
applicability of these measures to patients undergoing hepatec-
tomy has not previously been assessed. To determine the applica-
bility of NSQIP general risk models (as measured by morbprob and
mortprob statistics) to hepatic surgery, the 75th percentile morb-
prob and mortprob values were compared with observed rates of
major complications and mortality in the hepatectomy patients.
Major morbidity was defined by the occurrence of at least one
of the following complications: organ space infection; pneumo-
nia; unplanned intubation; pulmonary embolism; ventilator
requirement for >48 h; progressive renal insufficiency; acute renal
failure; cerebrovascular accident; coma; cardiac arrest; myocardial
infarction; deep venous thrombosis; sepsis; septic shock, and
return to operating room.
To identify clinical variables associated with 30-day major mor-
bidity and 30-day mortality following hepatectomy, univariate
analysis with chi-squared tests for categorical data and Mann–
Whitney U-tests for continuous data were used. Clinical variables
with univariate association with these two outcome endpoints at a
significance level of P < 0.05 were entered into Cox proportional
hazards models to determine independent associations with out-
comes. A P-value <0.05 in multivariate analysis was used to deter-
mine final significance. All statistical calculations were performed
using spss Version 14.0 (SPSS, Inc., Chicago, IL, USA).
Results
The median age of the 2313 hepatectomy patients in the dataset
was 60 years (range 18–90 years), their sex distributions were
equivalent and 78% were White. With regard to preoperative
risk factors, 65% of patients had an ASA (American Society of
Anesthesiologists) score of 3 or 4. No hepatectomy patients were
classified as ASA 5. The most prevalent co-morbidity was hyper-
tension (46%). Overall, 15% of patients were smokers and 14%
had diabetes mellitus. A total of 10% of patients complained of
dyspnoea on exertion, but only 3% carried a diagnosis of chronic
lung disease. Only 4% had been treated with a coronary artery
intervention. A total of 41% of patients underwent hepatectomy
for disseminated cancer, 19% of whom had received chemo-
therapy within 30 days of surgery (Table 1).
The 30-day major morbidity rate was 19.6% (453/2313). Major
morbidity rates correlated with the extent of hepatic resection
(Table 2). The 30-day major morbidity rates for patients treated
with partial, left, right and extended hepatectomy were 16.8%,
15.7%, 25.9% and 31.9%, respectively. With regard to major
morbidity, multivariate analysis identified five independent
preoperative risk factors (Table 3). Operative factors associated
with major morbidity included extent of hepatectomy operative
time, intraoperative red blood cell transfusion, and early post-
operative transfusion (Table 3).
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The 30-day mortality rate for all hepatectomy patients was
2.5% (57/2313). As with major morbidity, mortality rates paral-
leled the extent of hepatic resection. The 30-day mortality rates for
patients treated with partial, left, right and extended hepatectomy
were 1.8%, 0.9%, 3.7% and 5.2%, respectively. Univariate and
multivariate analyses were examined to determine associations
with perioperative risk factors and postoperative 30-day mortal-
ity. This analysis determined that the two risk variables that
Table 1 Clinical characteristics of 2313 hepatectomy patients in the National Surgical Quality Improvement Program (NSQIP) dataset. Values
are n (%) unless otherwise stated
Strata Variable Subset Descriptor
Preoperative Median age (range) 60 years (17–90 years)
Gender Male 1141 (49%)
Female 1172 (51%)
Race White 1799 (78%)
Other 514 (22%)
ASA score 1–2 821 (35%)
3–4 1492 (65%)
Median BMI (range) 27 m/kg2 (10–81 m/kg2)
Diabetes None 1976 (85%)
NIDDM 239 (10%)
IDDM 98 (5%)
Smoking No 1959 (85%)
Yes 354 (15%)
Functional status Independent 2273 (98%)
Partially dependent 33 (1%)
Totally dependent 7 (1%)
Dyspnoea on exertion No 2082 (90%)
Yes 231 (10%)
Previous coronary intervention No 2224 (96%)
Yes 89 (4%)
Hypertension No 1260 (55%)
Yes 1053 (45%)
Cancer No 1357 (59%)
Yes 956 (41%)
Preoperative chemotherapy No 2115 (91%)
Yes 198 (9%)
BMI loss >10% No 2187 (95%)
Yes 126 (5%)
Biochemistry Median creatinine (range) 1 mg/dl (1–10 mg/dl)
Median albumin (range) 4 mg/dl (2–6 mg/dl)
Median bilirubin (range) 0 mg/dl (0–15 mg/dl)
Median glutamic oxaloacetic transaminase (range) 96 mg/dl (8–837 mg/dl)
Median alkaline phosphatase (range) 101 mg/dl (32–1000 mg/dl)
Median prothrombin time (range) 12 s (8–40 s)
Median partial thromboplastin time (range) 28 s (11–85 s)
Median morbprob (range) 0.36 (0.04–0.90)
Median mortprob (range) 0.01 (0.0005–0.60)
Perioperative Extent of resection Partial hepatectomy 1344 (58%)
Hemi-hepatectomy 740 (32%)
Extended hepatectomy 229 (10%)
Median operative time (range) 232 min (18–1029 min)
Intraoperative red cell transfusion No 1646 (73%)
Yes 662 (27%)
Postoperative Postoperative red cell transfusion No 2292 (99%)
Yes 21 (1%)
Median postoperative length of stay (range) 8 days (0–138 days)
ASA, American Society of Anesthesiologists; BMI, body mass index; NIDDM, non-insulin dependent diabetes mellitus; IDDM, insulin dependent
diabetes mellitus
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strongly correlated with death in the 57 patients who died follow-
ing hepatectomy were elevated serum bilirubin prior to surgery
(P = 0.002, odds ratio [OR] 5.98, 95% confidence interval [CI]
1.091–18.860) and the need for intraoperative red cell transfusion
(P = 0.037, OR 2.5, 95% CI 1.055–5.947).
In addition, morbprob and mortprob statistics were examined
to determine their prognostic potential. A 75th percentile morb-
prob (0.40) was associated with a major complication positive
predictive value of only 29.8%, with a sensitivity of 50.8% and
a specificity of 70.9%. A 75th percentile mortprob (0.0315) was
associated with a major complication positive predictive value of
only 6.1%, with a sensitivity of 61.4% and a specificity of 75.9%.
One of the most important factors for mortality following
hepatectomy was the development of major morbidity. Patients
with minor morbidities were far less likely to experience a cata-
strophic event. By contrast, patients who developed major mor-
bidityexperienced a longer median length of stay (10 vs. 6 days;
P = 0.001) and a higher mortality rate (11.3% vs. 0.3%; P = 0.001).
Discussion
The purpose of this study was to determine the current status of
hepatic resection in the USA by analysing the NSQIP dataset.
Analysis of this multi-institutional experience with hepatectomy
indicates that the current mortality and major morbidity rate
benchmarks are 2.5% and 19.6%, respectively. The examined
dataset represents a broad analysis of hepatectomy types, practice
environments and patient risk factors. The results of this analysis
are supported by the strengths of the NSQIP structure, including
independent nurse data recording and mandatory 30-day follow

















Total 2313 (100) 1344 (58) 230 (10) 510 (22) 229 (10)
Organ space infection 138 (6.0) 61 (4.5) 12 (5.2) 40 (7.8) 25 (10.9) 0.0001
Pneumonia 93 (4.0) 41 (3.1) 8 (3.5) 28 (5.5) 16 (7.0) 0.009
Unplanned intubation 85 (3.7) 39 (2.9) 6 (2.6) 24 (4.7) 16 (7.0) 0.009
Pulmonary embolism 38 (1.6) 16 (1.2) 1 (0.4) 13 (2.5) 8 (3.5) 0.011
Ventilator requirement for >48 h 101 (4.4) 43 (3.2) 7 (3.0) 34 (6.7) 17 (7.4) 0.001
Progressive renal insufficiency 15 (0.6) 5 (0.4) 1 (0.4) 7 (1.4) 2 (0.9) 0.107
Acute renal failure 35 (1.5) 13 (1.0) 1 (0.4) 16 (3.1) 5 (2.2) 0.003
Cerebrovascular accident 11 (0.5) 4 (0.3) 1 (0.4) 3 (0.6) 3 (1.3) 0.220
Coma 0 (0.3) 4 (0.3) 0 (0) 1 (0.2) 1 (0.4) 0.794
Cardiac arrest 25 (1.1) 10 (0.7) 1 (0.4) 10 (2.0) 4 (1.7) 0.073
Myocardial infarction 8 (0.3) 5 (0.4) 0 (0) 2 (0.4) 1 (0.4) 0.823
Deep venous thrombosis 47 (2.0) 17 (1.3) 4 (1.7) 14 (2.7) 12 (5.2) 0.001
Sepsis 154 (6.7) 77 (5.7) 12 (5.2) 43 (8.4) 22 (9.6) 0.038
Septic shock 86 (3.7) 36 (2.7) 5 (2.2) 26 (5.1) 19 (8.3) 0.000
Return to operating room 112 (4.8) 46 (3.4) 11 (4.8) 37 (7.3) 18 (7.9) 0.001
Table 3 Analysis of clinical factors in the National Surgical Quality Improvement Program database associated with major morbidity following
hepatectomy
Strata Risk factor MV P-value Odds ratio
Preoperative ASA score 0.001 1.4
Smoking 0.0001 1.7
Biochemistries Elevated alkaline phosphatase 0.0001 4.9
Low albumin 0.006 2.8
Elevated partial thromboplastin time 0.047 2.0
Perioperative Extent of hepatectomy 0.0001 1.8
Intraoperative red cell transfusion 0.0001 2.2
Prolonged operative time 0.011 1.6
Postoperative red cell transfusion 0.001 1.4
MV, multivariate; ASA, American Society of Anesthesiologists
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up. These tenets insure the most accurate reporting of surgical risk
factors and outcomes compared with previously analysed multi-
institutional datasets.
Analysis of the hepatectomy subset of cases in the NSQIP deter-
mined that poor outcomes were not associated with age or body
mass index. Instead, poor outcomes were most dependent on
nutritional status, liver function at the time of hepatectomy, and
the extent of resection. In fact, major morbidity rates closely
correlated with the extent of resection. Only 17% of patients with
partial hepatectomy experienced a major complication, whereas
hemihepatectomy patients experienced a 23% major morbidity
rate and extended hepatectomy patients experienced the highest
major morbidity rate at 32%. Likewise, mortality rates correlated
with the extent of hepatectomy, with the highest mortality rates
experienced by patients undergoing right hepatectomy (3.7%)
and extended hepatectomy (5.2%).
In comparison with recently published mortality rates for
hepatectomy, the mortality rates in the NSQIP dataset may
appear alarmingly elevated. In fact, several specialty centres have
reported large-volume experiences with minimal to no operative
mortality.2–6,8–10,15–17 However, the NSQIP hepatectomy mortality
rates closely correlate with two recent analyses of the National
Inpatient Sample.1,18 One of these analyses included 11 429 hepa-
tectomy patients and found an overall mortality rate of 5.6%, 1.6
times higher than an aggregate of recently published mortality
rates.18 Combined, these data suggest that a broader, and more
objective, analysis of morbidity and mortality may result in
a realistic assessment of the current risk associated with hepatec-
tomy, facilitating comparison between programmes and the devel-
opment of institution-specific quality improvement initiatives.
The data points in the NSQIP PUF allowed for a detailed analysis
of risk and outcome in a large cohort of patients. The NSQIP was
not, however, specifically designed to comment on this subset of
surgical patients. Therefore, several data points of interest are not
included in this analysis. Firstly, the categorization of anaesthesia
type in the NSQIP does not differentiate general anaesthesia from
epidural anaesthesia when both modalities are utilized. Based on
the lack of detail in this area, no specific comments can be made
regarding the ongoing discussion of the use of epidural anaesthesia
in hepatic surgery and its possible association with poor outcomes,
including elevated transfusion rates.19,20 Secondly, data collection
ends at 30 postoperative days. Given that recent reports suggest that
delayed hepatic regeneration may lead to elevated 90-day mortality
rates following hepatectomy,7,21 this may be viewed as a weakness of
this dataset. However, late mortality (from 31–90 postoperative
days) remains a rare occurrence and should not detract from the
mortality risk analysis included here.
In addition, the PUF database does not allow for the tracking of
cases to specific institutions or surgeons and therefore we cannot
verify the contribution of programme experience, hospital size
and surgeon-specific experience to these results. Further experi-
ence with data analysis from the PUF and the formation of
working groups to allow extraction and evaluation of site-specific
data may allow more detailed appraisal of outcomes associated
with these relevant factors.
The secondary goal of this analysis was to determine the ability
of the general NSQIP dataset to comment on a specialty-specific
area in HPB surgery, such as hepatectomy. The large number
of patients and variables contained in the NSQIP PUF clearly
facilitated one of the most detailed multicentre examinations of
morbidity and mortality in hepatectomy patients, identifying
multiple independent prognostic factors. However, the analysis
determined that the general surgical risk models created from
the entire NSQIP database, as reflected in the general surgical
morbprob and mortprob statistics, are relatively inaccurate at pre-
dicting actual morbidity and mortality in hepatectomy patients.
Further study will be needed to determine if similar discrepancies
apply toother complex elective or emergency operations. Reap-
praisal of risk modelling methods for this cohort of procedures
may be warranted.
This finding indicates that patients undergoing hepatectomy
have a unique risk to outcome relationship that differs from that
in a general population of surgical patients. For the NSQIP to
accurately comment on this relationship requires that two issues
are addressed. Firstly, the NSQIP might use its robust statistical
core to validate the findings of this study and to create a
hepatectomy-specific mortprob and morbprob statistic from the
variables currently recorded in the NSQIP database. Based on our
analysis of the current version of variables included in NSQIP data
collection, adding the prognostic risk factors we identified to the
risk modelling would result in a hepatobiliary-specific morbprob
and mortprob with significantly more predictive strength.
Table 4 Suggested hepatobiliary-specific additions to the current list
of recorded National Surgical Quality Improvement Program pre-
operative risk factors, perioperative data points and outcome
measures
• Preoperative variables/risk factors
 Presence of biliary obstruction
 Presence of indwelling biliary drainage catheters
 Portal vein embolization
 Neoadjuvant chemotherapy details (drugs, cycles, duration)
 Preoperative Model for End-stage Liver Disease (MELD) score
• Perioperative variables/risk factors
 Use of epidural anaesthesia
 Liver transection technique
 Combined resection/ablation procedure
 Bilio-enteric reconstruction
 Use of perihepatic drains
 Histology of tumour(s)
 Histologic condition of the non-tumoral liver
• Postoperative occurrences (complications)
 Deep surgical space infection with vs. without biloma
 Peak postoperative bilirubin
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Secondly, the hepatobiliary-specific models might be further
strengthened by the addition of hepatectomy patient-specific pre-
operative and perioperative risk variables. For example, the
NSQIP might add the presence of biliary drainage catheters and
the need for biliary reconstruction at the time of hepatectomy to
the list of preoperative and perioperative variables collected in
NSQIP hepatectomy patients. Likewise, the risk model might be
strengthened by the addition of hepatectomy-specific outcomes
measures, such as bile leak. It is likely that this outcome is captured
in the ‘organ space infection’ category; however, further refine-
ment to clarify the presence of bile leak vs. other organ space
infection would add specificity to the data collection. A detailed
listing of suggested hepatobiliary-specific additions to the current
list of recorded NSQIP risk factors, perioperative data points and
outcomes measures is included in Table 4.
This study reveals that the American College of Surgeons (ACS)
NSQIP risk models currently in use do not accurately predict
outcomes for patients undergoing hepatectomy. A major strength
of the ACS-NSQIP PUF is that this multi-institutional verified
database produces a more generalizable view of outcomes and risk
stratification of patients undergoing hepatectomy. In order to opti-
mize programmatic and surgeon-specific comparisons, ongoing
reappraisal of risk models and the development of analytic tools
and metrics for specific high-risk procedures will be needed. The
deficiencies of the NSQIP in predicting post-hepatectomy out-
comes highlighted in this discussion should not, however, detract
from the power of this dataset. The NSQIP, even in its current state,
is the most robust and comprehensive multi-institutional database
available to assess surgical risk in these patients. Our analysis of the
current NSQIP hepatectomy dataset identified multiple significant
and independent variables that can be used by hepatobiliary sur-
geons, their patients and referring physicians to estimate the mor-
bidity and mortality risks of major hepatic resection.
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